December 10, 2016 9:31 PM ET

Pharmaceuticals

Company Overview of Phibro Animal Health Corporation

Company Overview

Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. Its animal health products also include antibacterials that are biological or chemical products used in the animal health industry to treat or to prevent diseases; anticoccidials primarily used to prevent and control the disease coccidiosis in poultry and cattle; anthelmintics to treat infestations of parasitic inte...

Glenpointe Centre East

3rd Floor

Suite 21

300 Frank West Burr Boulevard

Teaneck, NJ 07666

United States

1,300 Employees

Phone:

201-329-7300

Fax:

201-329-7399

Key Executives for Phibro Animal Health Corporation

Chairman, Chief Executive Officer, President and Member of Compensation Committee
Age: 69
Total Annual Compensation: $2.5M
Chief Financial Officer
Age: 67
Total Annual Compensation: $664.7K
Chief Operating Officer
Age: 52
Total Annual Compensation: $652.7K
Compensation as of Fiscal Year 2016.

Phibro Animal Health Corporation Key Developments

Phibro Animal Health Corporation Reports Consolidated Earnings Results for the Third Quarter Ended September 30, 2016; Provides Earnings Guidance for the Full Year of 2016; Reaffirms Earnings Guidance for the Full Year of 2017

Phibro Animal Health Corporation reported consolidated earnings results for the third quarter ended September 30, 2016. For the quarter, the company reported net sales of $188 million, operating income of $21.8 million, income before income taxes of $17.6 million, net income of $12.2 million or $0.31 per diluted share against net sales of $187.1 million, operating income of $21.9 million, income before income taxes of $23.5 million, net income of $18.8 million or $0.47 per diluted share a year ago. EBITDA of $27.8 million and adjusted EBITDA of $29.8 million against EBITDA of $32.7 million and adjusted EBITDA of $27.7 million a year ago. Adjusted net income of $14.6 million compared to $13.8 million a year ago. Net cash provided by operating activities of $21.5 million compared to net cash used in operating activities of $2.4 million a year ago. Capital expenditures were $5.9 million compared to $8.1 million a year ago. The decrease in net income was a result of the factors, including a $5.8 million decline in foreign currency (gains) losses, net and a $0.7 million increase in income tax expense. For the full year of 2016, the company expects net sales to be $752 million, adjusted EBITDA to be $114 million, operating income to be $96 million, income before income taxes to be $81 million, net income to be $57 million or $1.43 per diluted share. The company maintained full year CapEx guidance of $30 million. For the full year of 2017, the company reaffirms net sales to be $750 million to $770 million, adjusted EBITDA to be in the range of $116 million to $120 million, operating income to be $95 million to $99 million, income before income taxes to be $78 million to $82 million, net income to be $55 million to $58 million or $1.38 to $1.45 per diluted share.

Phibro Animal Health Corporation Declares Quarterly Dividend, Payable on December 21, 2016

The Board of Directors of Phibro Animal Health Corporation declared a quarterly cash dividend of $0.10 per share on its Class A common stock and Class B common stock, payable on December 21, 2016, to stockholders of record at the close of business on November 30, 2016.

Phibro Animal Health Corporation to Report Q1, 2017 Results on Nov 09, 2016

Phibro Animal Health Corporation announced that they will report Q1, 2017 results at 5:00 PM, Eastern Standard Time on Nov 09, 2016

Similar Private Companies By Industry

Company Name Region
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States
7 Oaks Pharmaceutical Corp. United States

Recent Private Companies Transactions

Type
Date
Target
Merger/Acquisition
January 12, 2016
MVP Laboratories, Inc.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Phibro Animal Health Corporation, please visit www.pahc.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.